Hartmann Andreas

MD

My medical studies and neurology internship (neurology enlaced with psychiatry and neurosurgery) were done in Germany.

From 1997-2000, I worked as a postdoctoral fellow on Parkinson disease (PD) in Paris (INSERM U289/675, Hôpital de la Pitié-Salpêtrière) on the role of programmed cell death in the pathophysiology of this disorder. Upon completion of my internship in 2003 (Phillips-Universität Marburg, Germany), I returned to Paris to work as a neurologist sub-specialized in movement disorders. In parallel to ongoing work on the molecular and cellular biology of PD and a special interest in clinical neuroprotection studies relevant to PD, I made the acquaintance of Gilles de la Tourette syndrome (TS) through a multicenter national study which I coordinated from 2004-2007.

After we successfully applied for the creation of a French Reference Center for TS in 2007, my clinical and research interest have since then shifted to TS. Currently, I am the coordinator of the French Reference Centre for TS and past chair (2017-2020) of the European Society for the Study of Tourette Syndrome (ESSTS).

-Medical Studies: University of Munich,Germany, 1986 – 1993

-Foreign electives in Hong Kong (Queen Elizabeth University), London (Royal Free Hospital and Institute of Neurology,Queen Square), New York (Mount Sinai Medical School) and Boston (Harvard Medical School)

-MD Thesis: University of Munich, 1994 (Auswirkungen von CRH, ACTH 4-9 und Cortisol auf späte akustische evozierte   Potentiale bei Normalpersonen)        

Laboratory : Max-Planck-Institut für Psychiatrie, Klinisches Institut, Munich

-Habilitation: July 2002,University of Marburg/Germany

French equivalent „Habilitation à diriger les Recherches“ (HDR) at the University Pierre and Marie Curie (Paris VI) in October 2004

-Internship/Residency: Psychiatry and Clinical Electrophysiology, Max-Planck-Insititute of Psychiatry, Munich,Germany, 1993 –1995

-Residency: Clinical Neurosurgery,University of Heidelberg, Klinikum Mannheim, Germany, 1995 – 1996

-Residency: Clinical Neurology, University of Marburg, Germany, 1996 – 1997

-Postdoctoral fellowship: INSERM U 289, Hôpital de la Salpêtrière, Paris, France, 1997 – 2000

-Residency: Clinical Neurology, University of Marburg, Germany, 2001 – 2003

-Poste Vert INSERM U 289/679, Salpêtrière, Paris ; and Attaché des Hôpitaux de Paris, Fédération de Maladies du Système Nerveux,Hôpital de la Salpêtrière, Paris, France: May 2003 -> April 2006

-Médecin délégué, Centre d’Investigation Clinique,Fédération de Maladies du Système Nerveux, Hôpital de la Salpêtrière, Paris, France: May 2006 -> October 2007  

-Praticien hospitalier temps plein(full-time consultant/attendant) since July 2009

-HartmannA, Hunot S, MIchel PP, Muriel MP, Vyas S, Faucheux BA,Mouatt-Prigent A, Turmel H, Srinivasan A, Ruberg M, Evan GI, Agid Y, Hirsch EC(2000) Caspase-3: a vulnerability factor and a final effector in the apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 97:2875-2880.

 

-HartmannA, Troadec JD, Hunot S, Kikly K, Faucheux BA,Mouatt-Prigent A, Ruberg M, Agid Y, Hirsch EC (2001) Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson´s disease but pathwayinhibition results in neuronal necrosis. JNeurosci 21:2247-2255.

 

-Lu L, Neff F, Dun Z, Hemmer B, OertelWH, Schlegel J, Hartmann A (2004) Gene expression profiles derived from single cells in human postmortem brain. Brain Res Protoc13:18-25

 

-Palminteri S,Lebreton M, Worbe Y, Grabli D, Hartmann A, Pessiglione M (2009) Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromes. Proc Natl AcadSci USA 106:19179-19184.

 

-Schüpbach M, Corvol JC, Czernicki V, Ben Djebara M,Golmard JL, Agid Y, Hartmann A (2010) The segmental progression of early untreated Parkinson's disease: a novel approach to clinical rating. J NeurolNeurosurg Psychiatry 81:20–25.

 

-Worbe Y, Mallet M, Golmard JL,Béhar C, Durif F, Jalenques I, Damier P, Derkinderen P,Pollak P, Anheim M, Broussolle E, Xie-Brustolin J,Mesnage V, Mondon K, Viallet F, Jedynak P, BenDjebara M, Schüpbach M, Pelissolo A, Vidailhet M,Agid Y, Houeto JL, Hartmann A (2010) Repetitive behaviours in patients with Tourette syndrome: tics, compulsions, or both? PlosONE 5(9):e12959.

 

-Alvarez-FischerD, Fuchs D, Castagner C, Stettler O, Massiani-BeaudoinO, Moya KL, Bouillot C, Oertel WH,Lombès A, Faigle W, Joshi RL, HartmannA*, Prochiantz A (2011) Engrailed Proteins protect mouse midbrain dopaminergic neurons against mitochondrial complex I insults and regulate their physiology. Nat Neurosci14:1260-1266.(*co-senior authorship)

 

-Alvarez-Fischer D, Noelker C, Vulinović F, Grünewald A, Chevarin C,Klein C, Oertel WH, Hirsch EC, Michel PP, Hartmann A (2013) Bee venom and its component apamin as neuroprotective agents in a Parkinson disease mouse model.PLoS One Apr 18;8(4):e61700.

 

-Delorme C, Salvador A, Valabrègue R, Roze E, Palminteri S, Vidailhet M,de Wit S, Robbins R, Hartmann A, Worbe Y (2016) Enhance habit formation in Gilles de la Tourette syndrome. Brain 139 :605-615.

 

-Hartmann A, Müllner J,Meier N, Hesekamp H, van Meerbeeck P, Habert MO, Kas A, Tanguy ML, Mazmanian M, Oya H, Abuaf N, Gaouar H, Salhi S,Charbonnier-Beaupel F,Fievet MH, Galanaud D, Arguillere S, Roze E, Degos B,Grabli D, Lacomblez L,Hubsch C, Vidailhet M, Bonnet AM, Corvol JC, Schüpbach M(2016) Bee Venom for the Treatment of Parkinson Disease - A Randomized Controlled Clinical Trial. PloSOneJul 12;11(7):e0158235.

 

-Salvador A, Worbe Y, Delorme C, Coricelli G, Gaillard R, Robbins TW, HartmannA, Palminteri S (2017) Specific effect of a dopamine partial agonist on counterfactual learning: evidence from Gilles de la Tourette syndrome. Sci Rep 7:6292.

 

-Cravedi E, Deniau E, Giannitelli M, Pellerin H, Czernecki V, Priou T,Xavier J, Consoli A, Hartmann A, Cohen D (2018) Disentangling Tourette syndrome heterogeneity through hierarchical ascendant clustering. Dev Med Child Neurol 60:942-950.

 

-Depienne C, Ciura S, Trouillard O, Bouteiller D, LeitãO E, Nava C, Keren B, Marie Y, Guegan J, Forlani S, Brice A, Anheim M, Agid Y,Krack P, Damier P, Viallet F, Houeto JL, Durif F, Vidailhet M, Worbe Y, Roze E,Kabashi E, Hartmann A (2019) Association of Rare Genetic Variants in Opioid Receptors with Tourette Syndrome. Tremor Other Hyperkinet Mov doi: 10.7916/tohm.v0.693. eCollection 2019.

 

-Atkinson-Clement C, Porte CA, de Liege A, Klein Y, Delorme C, BerangerB, Valabregue R, Gallea C, Robbins TW, Hartmann A, Worbe Y (2021)Impulsive prepotent actions and tics in Tourette disorder underpinned by a common neural network. Mol Psychiatry26:3548-3557.

 

-Anderson S,Heijerman-Holtgrefe A, Hartmann A. Tourette syndrome support organisations around the world. In: Martino D, Leckman J. Tourette Syndrome, 2nd edition, Oxford University Press, UK. In press.

Retrospective and prospective analyses of deep brain stimulation inpatients with TS
Participation in multiple genetic consortia on TS with ongoing acquisition of DNA samples
Longitudinal studies on the adult course of TS
Schering-Preis der Deutschen Parkinson-Gesellschaft 2001
Förderpreis der Deutschen Parkinson-Vereinigung 2001

Supervisor PI for:

No items found.

If you are interested in joining our team, or wish to receive more information:

Get in touch!
GO BACK
Brand identity & UX :